In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Noxzema Shave Gels Debut To Target Women

This article was originally published in The Rose Sheet

Executive Summary

Universal Group is introducing Noxzema Shave Gel as the brand's first line of shaving creams targeted to women, the Los Angeles company said

You may also be interested in...

P&G Shaving Products Licensing Agreement To Enhance Noxzema, Old Spice

Procter & Gamble's decision to license out the marketing and development control for Old Spice and Noxzema shaving products will enhance the company's shaving product line, P&G said.

Noxzema Skin Fitness K-3 Triple-Blade Razor Bowing Under Licensing Deal

Procter & Gamble is expanding its Noxzema Skin Fitness skin care line into women's shave system and disposable razors under a licensing deal with private label company Universal Group (Los Angeles).

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts